DE

The Future Map · technological enabler · active

BioTech & Genomics

Maturity

4 / 5

Basis, source, vintage

Sequencing capability is effectively mature and its cost curve is the steepest in this book; clinical translation is far behind, and the score is the blend.

Source: NHGRI Genome Sequencing Program cost data (Wetterstrand) — ~$95m per genome in Sept 2001 to ~$500 by 2022; sub-$1,000 only from ~2019 (2001–2022)

What it is

Reading, interpreting and applying biological information — sequencing, diagnostics, and the biological engineering built on them.

What it does

It converted biology from an observational science into an engineering one. Sequencing cost fell faster than semiconductor cost over the same period, which is the sharpest exponential in this book.

Common misconception

That falling sequencing cost translates into clinical benefit at the same rate. Interpretation, evidence generation and clinical integration are each far slower, and each is the binding constraint somewhere.

Steepens

A megatrend runs at the pace of its shallowest enabler. Marginal links are shown but never set the pace.

What would change its gradient

Shares megatrends with

In the book

Why the Future Arrives Unevenly — Ch. 7 — The Inversion of the Population Pyramid · Ch. 12 — Reading the Ramp · Ch. 14 — How Hype Is Manufactured

Sources


See it in the map →

Cite this entry

Talin, B. (2026). BioTech & Genomics. The Future Map, dataset v0.4.0 (2026-09-07). https://futuremap.talin.digital/e/biotech-and-genomics/

Machine view: This entry as Markdown · The whole map as JSON

Updated 2026-09-02.